Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syn-Tech Chem & Pharm CoROCO:1777 81 Debt-to-EBITDA is 0.42 as of Jun. 2026, which is 61% below its 10-year median of 1.09. GuruFocus rates ROCO:1777 with a GF Score™ of 81/100 and a GF Value™ of NT$96.98 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 304 Biotechnology companies, Syn-Tech Chem & Pharm Co ranks better than 68.42% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Syn-Tech Chem & Pharm Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:1777'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.18 Med: 1.09 Max: 3.26
Current: 0.45
During the past 13 years, the highest Debt-to-EBITDA Ratio of Syn-Tech Chem & Pharm Co was 3.26. The lowest was 0.18. And the median was 1.09.
ROCO:1777's Debt-to-EBITDA is ranked better than 68.42% of 304
companies
in the Biotechnology industry
Industry Median: 1.215
vs ROCO:1777: 0.45
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Syn-Tech Chem & Pharm Co Debt-to-EBITDA Related Terms
Syn-Tech Chem & Pharm Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1777 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Syn-Tech Chem & Pharm Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syn-Tech Chem & Pharm Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syn-Tech Chem & Pharm Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Syn-Tech Chem & Pharm Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Syn-Tech Chem & Pharm Co (ROCO:1777) has a Debt-to-EBITDA of 0.42 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Syn-Tech Chem & Pharm Co. This is 61% below median its historical median of 1.09. Over the past decade, Syn-Tech Chem & Pharm Co's Debt-to-EBITDA has ranged from 0.18 to 3.26. According to the industry distribution chart, Syn-Tech Chem & Pharm Co ranks #96 out of 304 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Syn-Tech Chem & Pharm Co's Debt-to-EBITDA too high?
Syn-Tech Chem & Pharm Co's current Debt-to-EBITDA of 0.42 is 61% below median its 10-year median of 1.09. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 3.26. The Biotechnology industry median Debt-to-EBITDA is 1.22. Syn-Tech Chem & Pharm Co's value of 0.42 is 65.4% below this industry median. Based on the distribution chart, Syn-Tech Chem & Pharm Co ranks #96 out of 304 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Syn-Tech Chem & Pharm Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syn-Tech Chem & Pharm Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn-Tech Chem & Pharm Co ranks #96 out of 304 companies for Debt-to-EBITDA. This puts Syn-Tech Chem & Pharm Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.22. Syn-Tech Chem & Pharm Co's value of 0.42 is 65.4% below this benchmark. Historically, Syn-Tech Chem & Pharm Co's own Debt-to-EBITDA has ranged from 0.18 to 3.26 over the past decade. While the company's 10-year median is 1.09 vs. the industry median of 1.22, Syn-Tech Chem & Pharm Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syn-Tech Chem & Pharm Co's current Debt-to-EBITDA of 0.42 is 65.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Syn-Tech Chem & Pharm Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syn-Tech Chem & Pharm Co's current Debt-to-EBITDA is 0.42, which is 61% below median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn-Tech Chem & Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co (ROCO:1777) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$96.98, compared to a current price of NT$74.90 — trading 22.8% below its estimated fair value. The current Debt-to-EBITDA is 0.42, which is 61% below median its 10-year median of 1.09 and 65.4% below the Biotechnology industry median of 1.22. Syn-Tech Chem & Pharm Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Syn-Tech Chem & Pharm Co (ROCO:1777), the current Debt-to-EBITDA is 0.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syn-Tech Chem & Pharm Co (ROCO:1777) Overvalued in 2026?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co stock appears to be undervalued.
The current stock price of NT$74.90 is trading 22.8% below its estimated GF Value™ of NT$96.98.
GuruFocus considers Syn-Tech Chem & Pharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:1777:
Debt-to-EBITDA: 0.42 (61% below median its 10-year median of 1.09)
GF Value™: NT$96.98 vs. price of NT$74.90 (22.8% below fair value)
Industry Position: 65.4% below the Biotechnology median (#96 of 304)
No single metric tells the full story. See the ROCO:1777 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syn-Tech Chem & Pharm Co Ltd is engaged in the manufacture and sale of western medicines, veterinary drugs, food additives, cosmetics, and related businesses. It manufactures and sells Active Pharmaceutical Ingredients for domestic and foreign pharmaceutical companies and trade agents. Its products include Alfuzosin HCl, Atomoxetine HCl, Chlorzoxazone, Chlormezanone, Cloperastine HCl, Crotamiton, Diclofenac Epolamine, and others. It generates the majority of its revenue from Asia excluding Taiwan.
81GF Score
Get the complete analysis for ROCO:1777
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1777 has been successfully added to your 
